28199964|t|Blockade of Rho-associated protein kinase (ROCK) inhibits the contractility and invasion potential of cancer stem like cells
28199964|a|Recent studies have implicated the roles of cancer stem like cells (CSCs) in cancer metastasis. However, very limited knowledge exists at the molecular and cellular level to target CSCs for prevention of cancer metastasis. In this study, we examined the roles of contractile dynamics of CSCs in cell invasion and delineated the underlying molecular mechanisms of their distinct cell invasion potential. Using de-adhesion assay and atomic force microscopy, we show that CSCs derived from melanoma and breast cancer cell lines exhibit increased contractility compared to non-CSCs across all tumor types. In addition, CSCs possess increased ECM remodeling capacity as quantified by collagen degradation assay. More importantly, pharmacological blockade of Rho-associated protein kinase completely abolished the contractility and collagen degradation capacity of both CSCs and non-CSCs. In conclusion, our study demonstrates the importance of cell contractility in regulating invasiveness of CSCs and suggests that pharmacological targeting of ROCK pathway represents a novel strategy for targeting both CSCs and bulk population for the treatment of cancer metastasis.
28199964	0	8	Blockade	T169	C0332206
28199964	12	41	Rho-associated protein kinase	T116,T126	C0389995
28199964	43	47	ROCK	T116,T126	C0389995
28199964	49	57	inhibits	T052	C3463820
28199964	62	75	contractility	T043	C0007613
28199964	80	88	invasion	T046	C2699153
28199964	89	98	potential	T033	C0243095
28199964	102	124	cancer stem like cells	T025	C1956422
28199964	169	191	cancer stem like cells	T025	C1956422
28199964	193	197	CSCs	T025	C1956422
28199964	202	219	cancer metastasis	T191	C2939420
28199964	267	295	molecular and cellular level	T080	C0441889
28199964	299	305	target	T169	C1521840
28199964	306	310	CSCs	T025	C1956422
28199964	315	325	prevention	T080	C2700409
28199964	329	346	cancer metastasis	T191	C2939420
28199964	388	408	contractile dynamics	T070	C3826426
28199964	412	416	CSCs	T025	C1956422
28199964	420	433	cell invasion	T046	C2699153
28199964	464	484	molecular mechanisms	T044	C3537153
28199964	503	516	cell invasion	T046	C2699153
28199964	517	526	potential	T033	C0243095
28199964	534	551	de-adhesion assay	T059	C0022885
28199964	556	579	atomic force microscopy	T059	C0242849
28199964	594	598	CSCs	T025	C1956422
28199964	612	620	melanoma	T025	C1513095
28199964	625	649	breast cancer cell lines	T025	C1512505
28199964	658	667	increased	T081	C0205217
28199964	668	681	contractility	T043	C0007613
28199964	694	702	non-CSCs	T025	C0038250
28199964	714	725	tumor types	T033	C4263544
28199964	740	744	CSCs	T025	C1956422
28199964	753	762	increased	T081	C0205217
28199964	763	766	ECM	T024	C0015350
28199964	767	777	remodeling	UnknownType	C0678692
28199964	778	786	capacity	T081	C1516240
28199964	804	812	collagen	T116	C0009325
28199964	813	830	degradation assay	T059	C0022885
28199964	850	874	pharmacological blockade	T169	C0332206
28199964	878	907	Rho-associated protein kinase	T116,T126	C0389995
28199964	933	946	contractility	T043	C0007613
28199964	951	980	collagen degradation capacity	T044	C1157968
28199964	989	993	CSCs	T025	C1956422
28199964	998	1006	non-CSCs	T025	C0038250
28199964	1069	1082	contractility	T043	C0007613
28199964	1097	1109	invasiveness	T046	C0920779
28199964	1113	1117	CSCs	T025	C1956422
28199964	1136	1161	pharmacological targeting	T043	C0599894
28199964	1165	1169	ROCK	T116,T126	C0389995
28199964	1170	1177	pathway	T044	C1148560
28199964	1210	1219	targeting	T043	C0599894
28199964	1225	1229	CSCs	T025	C1956422
28199964	1258	1267	treatment	T061	C0087111
28199964	1271	1288	cancer metastasis	T191	C2939420